ImmunoQure AG
Königsallee 90
Düsseldorf
40212
Germany
Tel: 49-211-1684-9336
Website: http://www.immunoqure.com/
Email: info@immunoqure.com
About ImmunoQure AG
ImmunoQure AG is a young biotech company spearheading the research and development of human-derived antibodies (HD-MABs) for the treatment of human diseases. Through our unique access to rare patient populations, we are able to identify patients harboring naturally optimized antibodies against key drug targets that are involved in preventing a number of human diseases.CLINICAL TRIAL
Please click here for clinical trial information.
3 articles about ImmunoQure AG
-
ImmunoQure AG and Memo Therapeutics AG announce collaboration for the production of APS-1 cognate, paired libraries
10/25/2019
ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases and Memo Therapeutics AG, a biotechnology company focused on the discovery and development of therapeutic antibodies from cognate paired antibody libraries today announced the establishment of a collaborative partnership to create libraries from APS-1 memory B cells.
-
ImmunoQure AG and Servier Enter Into Strategic Partnership for the Development of an Interferon-Alpha Human Autoantibody
2/14/2018
ImmunoQure and Servier will work collaboratively to advance ImmunoQure's therapeutic human Interferon-alpha autoantibody through preclinical development and into the clinic.
-
ImmunoQure Announces Publication In Cell Of Naturally Occurring Patient-Derived Autoantibodies That Limit Human Diseases
7/18/2016